A medicine’s clinical or commercial status does not determine whether an athlete may use it under sport rules. For thymosin beta-4 and TB-500, the relevant 2026 World Anti-Doping Agency list explicitly names them. Athletes need an eligibility check that identifies the substance and governing rules before considering any proposed exposure.
What the 2026 list says
The WADA 2026 Prohibited List, effective January 1, 2026, includes thymosin beta-4 and its derivatives, with TB-500 as an example, in section S2.3. The section is prohibited at all times, meaning both in and out of competition under the Code. A claim that a product is intended only for injury recovery does not remove that listing.
The list’s named example also shows why a nickname search is insufficient. A derivative can be relevant even if a package uses different marketing language. Obtain the complete ingredient identity and present it to the appropriate anti-doping authority rather than relying on a seller’s statement that the material is a peptide or naturally occurring.
Do not generalize across thymosins
This named beta-4 entry should not be rewritten as a conclusion about every molecule containing “thymosin” in its name. Alpha-1 is a different substance and needs its own complete assessment. Conversely, not finding a familiar name in a keyword search is not an official clearance: classes, derivatives and other rules may still matter.
Sport eligibility is also distinct from medical benefit. A prohibited listing does not establish that a substance repairs injuries, while an early clinical paper does not override a sport rule. Keep those questions in separate columns when reviewing a proposed treatment.
Prepare an exact inquiry
- Identify the sport, governing body and applicable anti-doping rules.
- Provide the complete substance name, ingredients and proposed route.
- Ask the responsible authority about the current status and any applicable therapeutic-use process.
- Keep the written response and the date of the check.
Do not infer a detection window or safe stopping interval from a half-life study or a discussion forum. These are different questions, and an online schedule cannot provide eligibility assurance. This guide intentionally supplies no timing strategy for avoiding a positive test.
Check the correct effective year
This summary concerns the list in force during November 2026. Rules should be rechecked for the relevant future date, especially when planning treatment across a year boundary. Use the official current document and the athlete’s responsible authority. A dated, substance-specific answer is more useful than a general assurance that a clinic’s products are permitted in sport.
Sources and reading scope
Research draft prepared November 7, 2026. This is educational synthesis, not medical review or an individualized treatment recommendation. Check the linked original records and current labels before making a decision.